FDG-PET-Guided Metastasis Directed Radiation Therapy for the Treatment of Metastatic Hormone Sensitive Prostate Cancer, The PRTY Trial
Phase 2
125
about 4 years
18+
Male only
6 sites in IL
What this study is about
This trial is testing whether FDG-PET-guided metastasis directed radiation therapy (MDRT) combined with standard treatments works better than standard treatments alone in treating metastatic hormone sensitive prostate cancer. This treatment approach aims to target active cancer sites identified through FDG-PET scans.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive Radiation Therapy
- 2.Take Antiandrogen Therapy
- 3.Take Cytotoxic Chemotherapy
- +3 more
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You are randomly assigned, but you will know your treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: Complete response rate (Cohort 2), Progression free survival (PFS) (Cohort 1)
Secondary: Incidence of AEs of MDRT (Cohort 2), Incidence of adverse events (AEs) of metastasis directed radiation therapy (MDRT) (Cohort 1), Objective response rate (Cohort 2), PFS (Cohort 2), Radiographic PFS (rPFS) (Cohort 1)
imaging, radiation